Rhythm Pharmaceuticals/$RYTM
1D1W1MYTD1Y5YMAX
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
- Ticker
- $RYTM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 414
- Headquarters
- Boston, United States
- Website
- rhythmtx.com
RYTM Metrics
BasicAdvanced
$7.6B
-
-$3.12
1.97
-
Price and volume
Market cap
$7.6B
Beta
1.97
52-week high
$122.20
52-week low
$74.50
Average daily volume
658K
Financial strength
Current ratio
3.452
Quick ratio
3.004
Long term debt to equity
44.352
Total debt to equity
50.522
Interest coverage (TTM)
-10.86%
Profitability
EBITDA (TTM)
-199.55
Gross margin (TTM)
89.00%
Net profit margin (TTM)
-85.59%
Operating margin (TTM)
-83.62%
Effective tax rate (TTM)
-0.52%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
-30.96%
Return on equity (TTM)
-117.04%
Valuation
Price to revenue (TTM)
30.921
Price to book
73.51
Price to tangible book (TTM)
77.17
Price to free cash flow (TTM)
-50.707
Free cash flow yield (TTM)
-1.97%
Free cash flow per share (TTM)
-2.169
Growth
Revenue change (TTM)
53.51%
Earnings per share change (TTM)
3.21%
3-year revenue growth (CAGR)
76.32%
3-year earnings per share growth (CAGR)
-1.82%
10-year earnings per share growth (CAGR)
3.33%
What the Analysts think about RYTM
Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.
RYTM Financial Performance
Revenues and expenses
RYTM Earnings Performance
Company profitability
RYTM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.